Test Report Status

<u>Final</u>



Biological Reference Interval Units

PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR :	DR. BOB
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061XC002080	AGE/SEX : 47 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KAILM23037761	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 24/03/2024 11:19:31
NEW DELHI 110030	ABHA NO :	REPORTED :27/03/2024 15:17:16
8800465156		
	_i	۱

Results

HAEMATOLOGY - CBC					
MEDI WHEEL FULL BODY HEALTH CHECK UP BI	MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE				
BLOOD COUNTS, EDTA WHOLE BLOOD					
HEMOGLOBIN (HB)	15.6	13.0 - 17.0	g/dL		
RED BLOOD CELL (RBC) COUNT	5.37	4.5 - 5.5	mil/µL		
WHITE BLOOD CELL (WBC) COUNT	6.68	4.0 - 10.0	thou/µL		
PLATELET COUNT	288	150 - 410	thou/µL		
RBC AND PLATELET INDICES					
HEMATOCRIT (PCV)	46.3	40 - 50	%		
MEAN CORPUSCULAR VOLUME (MCV)	86.2	83 - 101	fL		
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.1	27.0 - 32.0	pg		
MEAN CORPUSCULAR HEMOGLOBIN	33.7	31.5 - 34.5	g/dL		
CONCENTRATION (MCHC) RED CELL DISTRIBUTION WIDTH (RDW)	13.5	11.6 - 14.0	%		
MENTZER INDEX	16.1	11.0 - 14.0	<i>/</i> 0		
MEAN PLATELET VOLUME (MPV)	10.1	6.8 - 10.9	fL		
	10.4	0.0 10.9			
WBC DIFFERENTIAL COUNT					
NEUTROPHILS	56	40 - 80	%		
LYMPHOCYTES	37	20 - 40	%		
MONOCYTES	03	2 - 10	%		
EOSINOPHILS	04	1 - 6	%		
BASOPHILS	00	< 1 - 2	%		

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.



Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist**





Page 1 Of 15

View Details







PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR :	DR. BOB
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0061XC002080 PATIENT ID : KAILM23037761 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :47 Years Male DRAWN : RECEIVED :24/03/2024 11:19:31 REPORTED :27/03/2024 15:17:16
Test Report Status Final	Besults Biological	Reference Interval Ilnits

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR <

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist**



View Report

Page 2 Of 15

View Details





PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR :	PR. BOB
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0061XC002080 PATIENT ID : KAILM23037761	AGE/SEX : 47 Years Male DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 24/03/2024 11:19:31 REPORTED :27/03/2024 15:17:16
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

~			
	HAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH CHECK U	P BELOW 40 MALE		
ERYTHROCYTE SEDIMENTATION RATE (ESR BLOOD	R),EDTA		
E.S.R METHOD : WESTERGREN METHOD	05	0 - 14	mm at 1 hr
GLYCOSYLATED HEMOGLOBIN(HBA1C), ED BLOOD	TA WHOLE		
HBA1C	5.3	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%
ESTIMATED AVERAGE GLUCOSE(EAG)	105.4	< 116.0	mg/dL

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

gtisha.

Dr. Itisha Dhiman

Pathologist

Dr. Tarun Sharma **Consultant Pathologist**





Page 3 Of 15

View Details





PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR :	R. BOB
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KAILM23037761 CLIENT PATIENT ID:	AGE/SEX :47 Years Male DRAWN : RECEIVED :24/03/2024 11:19:31 REPORTED :27/03/2024 15:17:16
Test Report Status Final	Results Biological	Reference Interval Units

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

Identifying patients at increased risk for diabetes (prediabetes).
 The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
 AGA (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to : 1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin. 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, failed increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist**



View Report

Page 4 Of 15

View Details





PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR : D	R. BOB
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL		AGE/SEX : 47 Years Male
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	10/12/12/00/101	DRAWN : RECEIVED : 24/03/2024 11:19:31
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :27/03/2024 15:17:16
	1	

Test Report Status	<u>Final</u>
--------------------	--------------

Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE A METHOD : FORWARD/REVERSE POSITIVE METHOD : FORWARD/REVERSE POSITIVE METHOD : FORWARD/REVERSE POSITIVE

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma Consultant Pathologist



View Report

Page 5 Of 15

View Details





ATIENT NAME : KAILASH CHANDRA REF. DOCTOR : DR. BOB				
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 006	1XC002080	AGE/SEX :47 Year	rs Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	i	M23037761	DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST	CLIENT PATIENT ID:		RECEIVED : 24/03/	2024 11.19.31
DELHI	ABHA NO :		REPORTED :27/03/	
NEW DELHI 110030 8800465156				202113.17.10
8800403130				
Test Report Status <u>Final</u>	Results	Biologic	al Reference Interv	al Units
	BIOCHEMISTRY			
MEDI WHEEL FULL BODY HEALTH CHECK UP	BELOW 40 MALE			
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR)	91	Pre-diat	: < 100 petes: 100-125 s: >/=126	mg/dL
METHOD : SPECTROPHOTOMETRY				
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : SPECTROPHOTOMETRY	107	70 - 140	0	mg/dL
LIPID PROFILE WITH CALCULATED LDL, SEI	RUM			
CHOLESTEROL, TOTAL	237 High		Desirable 39 Borderline High 0 High	mg/dL
	179 High	. 150 1	le une e l	ma/dl
TRIGLYCERIDES	179 nigii	200 - 49	99 Borderline High	mg/dL
METHOD : SPECTROPHOTOMETRY				
HDL CHOLESTEROL	46	< 40 Lo >/=60 l		mg/dL
METHOD : SPECTROPHOTOMETRY CHOLESTEROL LDL	155 High	< 100 C	Intimal	mg/dL
	y.	100 - 12 Near op 130 - 12 Borderli 160 - 18	29 timal/ above optima 59 ne High	-

gtisha

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist**

Page 6 Of 15 ۶D



Шá





靋

PERFORMED AT :



PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR : DR. BOB		
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0061 PATIENT ID : KAILN CLIENT PATIENT ID: ABHA NO :	XC002080 123037761	AGE/SEX :47 Years Male DRAWN : RECEIVED :24/03/2024 11:19:31 REPORTED :27/03/2024 15:17:16
Test Report Status <u>Final</u>	Results	Biologica	I Reference Interval Units
NON HDL CHOLESTEROL	191 High	Above De Borderlin High: 19	e: Less than 130 mg/dL esirable: 130 - 159 ne High: 160 - 189 0 - 219 h: > or = 220
VERY LOW DENSITY LIPOPROTEIN CHOL/HDL RATIO	35.8 High 5.2 High	= 30.0<br 3.3 - 4.4 Low Risk 4.5 - 7.0 Average 7.1 - 11. Moderate > 11.0	Risk 0 e Risk
LDL/HDL RATIO	3.4 High		Desirable/Low Risk Borderline/Moderate

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

]	Risk Stratification for ASCVD	(Atherosclerotic cardiovascular	r disease) by Lipid Association of India	
	Dialy Catagory			Ì

Risk Category		
Extreme risk group	A.CAD with > 1 feature of high risk group	
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =
	50 mg/dl or polyvascular disease	
Very High Risk	1. Established ASCVD 2. Diabetes with 2 1	major risk factors or evidence of end organ damage 3.
	Familial Homozygous Hypercholesterolemi	a
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ	
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary	
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque	
Moderate Risk	2 major ASCVD risk factors	
Low Risk	0-1 major ASCVD risk factors	
Major ASCVD (Ath	nerosclerotic cardiovascular disease) Risk Factors	
1. Age $>$ or $=$ 45 year	ears in males and $>$ or $= 55$ years in females 3. Current Cigarette smoking or tobacco use	
2. Family history of p	oremature ASCVD	4. High blood pressure
5. Low HDL		

Itisha

Dr. Itisha Dhiman Pathologist

Dr. Tarun Sharma **Consultant Pathologist**



Page 7 Of 15

÷,

View Details





PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR :	DR. BOB
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0061XC002080 PATIENT ID : KAILM23037761 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :47 Years Male DRAWN : RECEIVED :24/03/2024 11:19:31 REPORTED :27/03/2024 15:17:16
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug T	herapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	< OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD : SPECTROPHOTOMETRY	1.20 High	0.2 - 1.0	mg/dL
BILIRUBIN, DIRECT	0.10	0.0 - 0.2	mg/dL
BILIRUBIN, INDIRECT	1.10 High	0.1 - 1.0	mg/dL
METHOD : SPECTROPHOTOMETRY TOTAL PROTEIN	7.8	6.4 - 8.2	g/dL
METHOD : SPECTROPHOTOMETRY ALBUMIN	4.3	3.4 - 5.0	g/dL
METHOD : SPECTROPHOTOMETRY GLOBULIN	3.5	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO	1.2	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER ASPARTATE AMINOTRANSFERASE(AST/SGOT)	18	15 - 37	U/L
METHOD : SPECTROPHOTOMETRY ALANINE AMINOTRANSFERASE (ALT/SGPT)	35	< 45.0	U/L
METHOD : SPECTROPHOTOMETRY ALKALINE PHOSPHATASE	59	30 - 120	U/L
METHOD : SPECTROPHOTOMETRY GAMMA GLUTAMYL TRANSFERASE (GGT)	27	15 - 85	U/L
METHOD : SPECTROPHOTOMETRY LACTATE DEHYDROGENASE	162	85 - 227	, U/L
METHOD : SPECTROPHOTOMETRY	102	00 227	-, -

Dr. Itisha Dhiman Pathologist

Dr. Tarun Sharma Consultant Pathologist



View Details



Page 8 Of 15



PERFORMED AT :



PATIENT NAME : KAILASH CH	IANDRA	REF. DOCTOR : DR. BOB	
CODE/NAME & ADDRESS : C00013		61XC002080 AGE/SEX	:47 Years Male
ARCOFEMI HEALTHCARE LTD (ME		ILM23037761 DRAWN	:
F-703, LADO SARAI, MEHRAULIS DELHI	CLIENT PATIENT ID:	RECEIVED	:24/03/2024 11:19:31
NEW DELHI 110030	ABHA NO :	REPORTED	:27/03/2024 15:17:16
8800465156			
Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
BLOOD UREA NITROGEN (BUN	I), SERUM		
BLOOD UREA NITROGEN	7	6 - 20	mg/dL
METHOD : SPECTROPHOTOMETRY			
CREATININE, SERUM			
CREATININE	0.90	0.90 - 1.30	mg/dL
METHOD : SPECTROPHOTOMETRY			
BUN/CREAT RATIO			
BUN/CREAT RATIO	7.78	5.00 - 15.00	
METHOD : SPECTROPHOTOMETRY			
URIC ACID, SERUM			
URIC ACID	6.8	3.5 - 7.2	mg/dL
METHOD : SPECTROPHOTOMETRY			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD : SPECTROPHOTOMETRY	7.8	6.4 - 8.2	g/dL
ALBUMIN, SERUM			
ALBUMIN	4.3	3.4 - 5.0	g/dL
METHOD : SPECTROPHOTOMETRY			-
GLOBULIN			
GLOBULIN METHOD : CALCULATED PARAMETER	3.5	2.0 - 4.1	g/dL
gtisha.	Te		Page 9 Of 15
Dr. Itisha Dhiman Pathologist	Dr. Tarun Sharma Consultant Pathologist		
			View Details View Report
PERFORMED AT : Agilus Diagnostics Ltd. M/S S.S. Wellness Centre,Ground Floc Jodhpur, 342001 Bajasthan India	or,C-22,Shastri Nagar,Near Central Academy S	School Patien	



PATIENT NAME : KAILASH CHANDRA	REF. DOCT	TOR : DR. BOB
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0061XC002080 PATIENT ID : KAILM23037761	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 24/03/2024 11:19:31 REPORTED :27/03/2024 15:17:16
8800465156		
Test Report Status <u>Final</u>	Results Biol	ogical Reference Interval Units

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM	140	136 - 145	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			
POTASSIUM, SERUM	4.3	3.50 - 5.10	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			
CHLORIDE, SERUM	108 High	98 - 107	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s) GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

gtisha.

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist**



View Details



Page 10 Of 15



PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR :	PR. BOB
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0061XC002080 PATIENT ID : KAILM23037761 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :47 Years Male DRAWN : RECEIVED :24/03/2024 11:19:31 REPORTED :27/03/2024 15:17:16
Test Report Status Final	Results Biological	Reference Interval Units

urine

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides. Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents. NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

Real rational glucose level in comparison to post prantial glucose level may be seen due to effect of Oral Hypoglycaenics & Insulin treatment, kenal Glyosuria, Glycaenic below in comparison to post prantial glucose level may be seen due to effect of Oral Hypoglycaenics & Insulin treatment, Renal Glyosuria, Glycaenic index & response to food consumed, Alimentary Hypoglycaenia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM- **Bilirubin** is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

velow is coloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis.obstruction of bile ducts.cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels-Detary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum

protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist**





View Report

Page 11 Of 15

View Details





PATIENT NAME : KAILASH CHANDRA	R	REF. DOCTOR	DR. BOB		
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061X		AGE/SEX	:47 Years	Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL		23037761	DRAWN	:	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:		RECEIVED	: 24/03/202	4 11:19:31
NEW DELHI 110030	ABHA NO :		1		4 15:17:16
8800465156					
Test Report Status <u>Final</u>	Results	Biologic	al Reference	Interval	Units
CLIN	IICAL PATH - URINALYSI	S			
MEDI WHEEL FULL BODY HEALTH CHECK UP					
PHYSICAL EXAMINATION, URINE					
COLOR	PALE YELLOW				
APPEARANCE	CLEAR				
CHEMICAL EXAMINATION, URINE					
PH	5.0	4.7 - 7.	5		
SPECIFIC GRAVITY	1.030	1.003 -	-		
PROTEIN	NOT DETECTED	NOT DE			
GLUCOSE	NOT DETECTED	NOT DE	_		
KETONES	NOT DETECTED	NOT DE			
BLOOD	NOT DETECTED		TECTED		
BILIRUBIN	NOT DETECTED	NOT DE	TECTED		
UROBILINOGEN	NORMAL	NORMA	L		
NITRITE	NOT DETECTED	NOT DE	TECTED		
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DE	TECTED		
MICROSCOPIC EXAMINATION, URINE					
RED BLOOD CELLS	NOT DETECTED		TECTED		HPF
PUS CELL (WBC'S)	0-1	0-5			HPF
EPITHELIAL CELLS	0-1	0-5		/	HPF
CASTS	NOT DETECTED				
CRYSTALS	NOT DETECTED				
BACTERIA	DETECTED (OCCASIONAL)	NOT DE	TECTED		
METHOD : MICROSCOPIC EXAMINATION	. ,				

Itisha.

Dr. Itisha Dhiman Pathologist

1

Dr. Tarun Sharma Consultant Pathologist

Page 12 Of 15





5 🗖

View Details





PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR : D	R. BOB
F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0061XC002080 PATIENT ID : KAILM23037761 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :47 Years Male DRAWN : RECEIVED :24/03/2024 11:19:31 REPORTED :27/03/2024 15:17:16
Test Report Status Final	Results Biological	Reference Interval Units

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

gtis

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma Consultant Pathologist





Page 13 Of 15

View Details





PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR : D	R. BOB
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061XC002080	AGE/SEX : 47 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KAILM23037761	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 24/03/2024 11:19:31
NEW DELHI 110030	ABHA NO :	REPORTED :27/03/2024 15:17:16
8800465156		

Test	Report	Status	<u>Final</u>
------	--------	--------	--------------

Results

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE				
MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE				
THYROID PANEL, SERUM				
ТЗ	71.28 Low	80.0 - 200.0	ng/dL	
T4	2.83 Low	5.10 - 14.10	µg/dL	
TSH (ULTRASENSITIVE)	2.780	0.270 - 4.200	µIU/mL	

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism

Dr. Itisha Dhiman Pathologist

Dr. Tarun Sharma Consultant Pathologist





View Report

Page 14 Of 15

View Details





PATIENT NAME : KAILASH CHANDRA	REF. DOCTOR : D	DR. BOB
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL		AGE/SEX : 47 Years Male
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 24/03/2024 11:19:31
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :27/03/2024 15:17:16

ſest	Report	Status	<u>Final</u>
------	--------	--------	--------------

Results

Biological Reference Interval Units

8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
0	Troffinal/Low	INOTIMAI		0	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies
REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011.					

NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
 Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

9. In case of queries please call customer care

(91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma Consultant Pathologist





View Report

Page 15 Of 15

View Details

